Class information for:
Level 1: EBP1//RADIOBIOL CANC//PA2G4

Basic class information

ID Publications Average number
of references
Avg. shr. active
ref. in WoS
23757 281 41.0 91%



Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)



ID, lev.
above
Publications Label for level above
157 21931 BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE

Terms with highest relevance score



Rank Term Type of term Relevance score
(tfidf)
Class's shr.
of term's tot.
occurrences
Shr. of publ.
in class containing
term
Num. of
publ. in
class
1 EBP1 Author keyword 42 83% 9% 24
2 RADIOBIOL CANC Address 4 75% 1% 3
3 PA2G4 Author keyword 2 67% 1% 2
4 AUTOCRINE GROWTH REGULATION Author keyword 2 43% 1% 3
5 ERBB3 BINDING PROTEIN 1 Author keyword 1 100% 1% 2
6 M1B PROSTATE CANCER Author keyword 1 100% 1% 2
7 CLIN PHARMACOL NEW DRUGS DEV UNIT Address 1 25% 1% 3
8 ANDROGEN INDEPENDENT TUMORS Author keyword 1 50% 0% 1
9 APOPTOTIC CLEAVAGE Author keyword 1 50% 0% 1
10 CANC MOL IMAGING UNIT Address 1 50% 0% 1

Web of Science journal categories

Author Key Words



Rank Web of Science journal category Relevance score
(tfidf)
Class's shr.
of term's tot.
occurrences
Shr. of publ.
in class containing
term
Num. of
publ. in
class
LCSH search Wikipedia search
1 EBP1 42 83% 9% 24 Search EBP1 Search EBP1
2 PA2G4 2 67% 1% 2 Search PA2G4 Search PA2G4
3 AUTOCRINE GROWTH REGULATION 2 43% 1% 3 Search AUTOCRINE+GROWTH+REGULATION Search AUTOCRINE+GROWTH+REGULATION
4 ERBB3 BINDING PROTEIN 1 1 100% 1% 2 Search ERBB3+BINDING+PROTEIN+1 Search ERBB3+BINDING+PROTEIN+1
5 M1B PROSTATE CANCER 1 100% 1% 2 Search M1B+PROSTATE+CANCER Search M1B+PROSTATE+CANCER
6 ANDROGEN INDEPENDENT TUMORS 1 50% 0% 1 Search ANDROGEN+INDEPENDENT+TUMORS Search ANDROGEN+INDEPENDENT+TUMORS
7 APOPTOTIC CLEAVAGE 1 50% 0% 1 Search APOPTOTIC+CLEAVAGE Search APOPTOTIC+CLEAVAGE
8 EPIDERMIAL GROWTH FACTOR RECEPTOR 1 50% 0% 1 Search EPIDERMIAL+GROWTH+FACTOR+RECEPTOR Search EPIDERMIAL+GROWTH+FACTOR+RECEPTOR
9 HER 2 NEU PROTEIN 1 50% 0% 1 Search HER+2+NEU+PROTEIN Search HER+2+NEU+PROTEIN
10 HERCEPTEST TM 1 50% 0% 1 Search HERCEPTEST+TM Search HERCEPTEST+TM

Key Words Plus



Rank Web of Science journal category Relevance score
(tfidf)
Class's shr.
of term's tot.
occurrences
Shr. of publ.
in class containing
term
Num. of
publ. in
class
1 ERBB 3 BINDING PROTEIN 17 70% 5% 14
2 ANDROGEN INDEPENDENCE 8 19% 13% 36
3 BINDING PROTEIN EBP1 6 48% 4% 10
4 ERB B 2 NEU PROTOONCOGENE 6 71% 2% 5
5 P38 2G4 6 100% 1% 4
6 ERBB3 BINDING PROTEIN 4 67% 1% 4
7 EBP1 3 40% 2% 6
8 PROTEIN EBP1 3 60% 1% 3
9 HER 2 NEU ONCOPROTEIN 2 27% 3% 8
10 ERBB 3 2 33% 1% 4

Journals

Reviews



Title Publ. year Cit. Active references % act. ref.
to same field
Profiling serum HER-2/NEU in prostate cancer 2013 3 47 49%
Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond 2011 9 54 31%
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer 2001 30 26 35%
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu) 2010 8 34 18%
Her-2/neu receptor in prostate cancer development and progression to androgen independence 2004 23 79 22%
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer 2012 10 130 8%
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies 2006 99 215 5%
Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro 2006 15 79 13%
Kinase Inhibitors in Prostate Cancer 2009 1 134 10%
Smart drugs in prostate cancer 2004 27 166 7%

Address terms



Rank Address term Relevance score
(tfidf)
Class's shr.
of term's tot.
occurrences
Shr. of publ.
in class containing
term
Num. of
publ.
in class
1 RADIOBIOL CANC 4 75% 1.1% 3
2 CLIN PHARMACOL NEW DRUGS DEV UNIT 1 25% 1.1% 3
3 CANC MOL IMAGING UNIT 1 50% 0.4% 1
4 CHAIR UROL CLIN 1 50% 0.4% 1
5 LIFE SCI BIO PHARMACEUT 1 50% 0.4% 1
6 SANTO ANDRE 1 50% 0.4% 1
7 STATE OTOLARYNGOL HEAD NECK SURG 1 50% 0.4% 1
8 UNIV SURG CANC SCI MOL PATHOL 1 50% 0.4% 1
9 HUMAN COMPARAT PROSTATE CANC GENOM 0 33% 0.4% 1
10 JUNG STILLING HOSP 0 33% 0.4% 1

Related classes at same level (level 1)



Rank Relatedness score Related classes
1 0.0000192028 HER3//NUCLEAR EGFR//EGFR FAMILY
2 0.0000151250 ANDROGEN RECEPTOR//ANDROGEN INSENSITIVITY SYNDROME//ANDROGEN INSENSITIVITY
3 0.0000139865 LZTS1//UROGENE//NUCLEAR ROUNDNESS
4 0.0000137156 C ERBB 2//HER 2 NEU//P185
5 0.0000135534 ABIRATERONE//ENZALUTAMIDE//CASTRATION RESISTANT PROSTATE CANCER
6 0.0000117231 NIMOTUZUMAB//H R3//CETUXIMAB
7 0.0000108865 PROSTATE DEVELOPMENT//BIOL SCI VET MED//PROSTATE STEM CELL
8 0.0000108151 UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS
9 0.0000069128 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
10 0.0000066003 AGR2//C44A//LYPD3